Validated using a knockout cell line
Recombinant
RabMAb

Recombinant Anti-DFNA5/GSDME antibody [EPR19859] - N-terminal (ab215191)

Knockout Tested Rabbit recombinant monoclonal DFNA5/GSDME antibody [EPR19859]. Validated in WB, IP, Flow Cyt and tested in Mouse, Rat, Human. Cited in 2 publication(s).

Publishing research using ab215191? Please let us know so that we can cite the reference in this datasheet.

ab215191 has been referenced in 6 publications.

  • Zhang CC  et al. Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation. Apoptosis N/A:N/A (2019). PubMed: 30710195
  • Wu M  et al. A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma. EBioMedicine 41:244-255 (2019). PubMed: 30876762
  • Rogers C  et al. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. Nat Commun 10:1689 (2019). PubMed: 30976076
  • Tsuchiya K  et al. Caspase-1 initiates apoptosis in the absence of gasdermin D. Nat Commun 10:2091 (2019). PubMed: 31064994
  • Wang Y  et al. GSDME mediates caspase-3-dependent pyroptosis in gastric cancer. Biochem Biophys Res Commun 495:1418-1425 (2018). WB ; Human . PubMed: 29183726
  • Wang Y  et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a Gasdermin. Nature N/A:N/A (2017). PubMed: 28459430

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up